PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23437362-7	2013	The results imply that first and second generation of mTOR inhibitors promote over-activation of different pro-oncogenic pathways in PDAC cells, suggesting that suppression of feed-back loops should be a major consideration in the use of these inhibitors for PDAC therapy.	pdac	133-137	mechanistic target of rapamycin kinase	Homo sapiens	54-58	
28574828-4	2017	In this study, we investigated the antitumor efficacy of the novel PI3K and mTOR dual inhibitor VS-5584 in PDAC.	pdac	107-111	mechanistic target of rapamycin kinase	Homo sapiens	76-80	
29482945-8	2018	Furthermore, metformin could increase anti-proliferative effects of mTORC1 and PI3K/mTOR inhibitors as well as natural products such as berberine and the anti-malarial drug chloroquine in certain PDAC lines.	pdac	196-200	mechanistic target of rapamycin kinase	Homo sapiens	68-72	
25834145-3	2015	Our results demonstrate that CAF secretome-triggered chemoresistance is abolished upon inhibition of the protein synthesis mTOR/4E-BP1 regulatory pathway which we found highly activated in primary cultures of alpha-SMA-positive CAFs, isolated from human PDAC resections.	pdac	254-258	mechanistic target of rapamycin kinase	Homo sapiens	123-127	
23232026-10	2012	These findings demonstrate superior activity and support further in vivo evaluation of combined treatment with BEZ235 and PS against PDAC that possess heightened activity of RAS-RAF-ERK1/2 and PI3K-AKT-mTOR pathways.	pdac	133-137	mechanistic target of rapamycin kinase	Homo sapiens	202-206	
33273827-7	2020	The loss of PC4 in PDAC inhibits cell growth by inducing cell cycle arrest at the G1/S transition and suppressing the mTOR/p70s6k pathway.	pdac	19-23	mechanistic target of rapamycin kinase	Homo sapiens	118-122